Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma

[Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular...

Descripción completa

Detalles Bibliográficos
Autores principales: Hasan, Gulam Mustafa, Hassan, Md. Imtaiyaz, Sohal, Sukhwinder Singh, Shamsi, Anas, Alam, Manzar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398694/
https://www.ncbi.nlm.nih.gov/pubmed/37546685
http://dx.doi.org/10.1021/acsomega.3c02424
_version_ 1785084105924280320
author Hasan, Gulam Mustafa
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
Shamsi, Anas
Alam, Manzar
author_facet Hasan, Gulam Mustafa
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
Shamsi, Anas
Alam, Manzar
author_sort Hasan, Gulam Mustafa
collection PubMed
description [Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors.
format Online
Article
Text
id pubmed-10398694
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-103986942023-08-04 Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma Hasan, Gulam Mustafa Hassan, Md. Imtaiyaz Sohal, Sukhwinder Singh Shamsi, Anas Alam, Manzar ACS Omega [Image: see text] Non-small cell lung carcinoma (NSCLC) is the most common cancer globally. Phytochemicals and small molecule inhibitors significantly prevent varying types of cancers, including NSCLC. These therapeutic molecules serve as important sources for new drugs that interfere with cellular proliferation, apoptosis, metastasis, and angiogenesis by regulating signaling pathways. These molecules affect several cellular signaling cascades, including p53, NF-κB, STAT3, RAS, MAPK/ERK, Wnt, and AKT/PI3K, and are thus implicated in the therapeutic management of cancers. This review aims to describe the bioactive compounds and small-molecule inhibitors, their anticancer action, and targeting cellular signaling cascades in NSCLC. We highlighted the therapeutic potential of Epigallocatechin gallate (EGCG), Perifosine, ABT-737, Thymoquinine, Quercetin, Venetoclax, Gefitinib, and Genistein. These compounds are implicated in the therapeutic management of NSCLC. This review further offers deeper mechanistic insights into different signaling pathways that could be targeted for NSCLC therapy by phytochemicals and small-molecule inhibitors. American Chemical Society 2023-07-17 /pmc/articles/PMC10398694/ /pubmed/37546685 http://dx.doi.org/10.1021/acsomega.3c02424 Text en © 2023 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Hasan, Gulam Mustafa
Hassan, Md. Imtaiyaz
Sohal, Sukhwinder Singh
Shamsi, Anas
Alam, Manzar
Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title_full Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title_fullStr Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title_full_unstemmed Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title_short Therapeutic Targeting of Regulated Signaling Pathways of Non-Small Cell Lung Carcinoma
title_sort therapeutic targeting of regulated signaling pathways of non-small cell lung carcinoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398694/
https://www.ncbi.nlm.nih.gov/pubmed/37546685
http://dx.doi.org/10.1021/acsomega.3c02424
work_keys_str_mv AT hasangulammustafa therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma
AT hassanmdimtaiyaz therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma
AT sohalsukhwindersingh therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma
AT shamsianas therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma
AT alammanzar therapeutictargetingofregulatedsignalingpathwaysofnonsmallcelllungcarcinoma